EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CLX-155: A Novel, Oral 5-FU Prodrug Displaying Antitumor Activity in Human Colon Cancer Xenograft Model in Nude Mice

Natasha Boyette, Ava Dalton, Yearam Tak, Sophie Kang, Subbu Apparsundaram, Mahesh Kandula, John York

Medical Research Archives · 24.06.2024 · 12 (6)

DOI: 10.18103/mra.v12i6.5219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Research Archives, online erschienen am 24.06.2024. Verfasst von Natasha Boyette und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Capecitabine is an oral prodrug of 5-FU, which interpatient pharmacokinetic (PK) variability related to liver function and severe adverse events (e.g., hand-foot syndrome, myelosuppression, and neurotoxicity) limits. CLX-155 is a novel oral 5’-DFCR prodrug involving 5’-DFCR as an intermediate for generating 5-FU, unlike capecitabine, which the liver does not metabolize. This study addresses the following research question: what is the activity of CLX-155 in a human colon cancer xenograft model in nude mice?

Methods

This study involved 50 Foxn1 athymic nude female mice implanted with the human colon cancer cell line HCT116 (5 million cells per site). Investigators randomized animals into five treatment groups (N = 10): vehicle control, CLX-155 at doses of 125, 250, and 500 mg/kg/day, or capecitabine 1000 mg/kg/day. Animals received oral treatment once daily for five days a week with two days off for a total of three consecutive weeks. Investigators evaluated treatment toxicity based on body weight loss. Calculations for tumor growth inhibition involved comparing changes in tumor volume on a given day to tumor volumes on Day 1.

Results

CLX-155 demonstrated statistically significant, dose-dependent tumor growth inhibition at all doses compared to vehicle control (p

Zitieren

APA

Boyette, N., Dalton, A., Tak, Y., Kang, S., Apparsundaram, S., Kandula, M., & York, J. (2024). CLX-155: A Novel, Oral 5-FU Prodrug Displaying Antitumor Activity in Human Colon Cancer Xenograft Model in Nude Mice. Medical Research Archives, 12(6). https://doi.org/10.18103/mra.v12i6.5219

Vancouver

Boyette N, Dalton A, Tak Y, Kang S, Apparsundaram S, Kandula M, et al. CLX-155: A Novel, Oral 5-FU Prodrug Displaying Antitumor Activity in Human Colon Cancer Xenograft Model in Nude Mice. Medical Research Archives. 2024;12(6). doi:10.18103/mra.v12i6.5219

BibTeX
@article{Boyette2024,
  author = {Boyette, Natasha and Dalton, Ava and Tak, Yearam and Kang, Sophie and Apparsundaram, Subbu and Kandula, Mahesh and York, John},
  title = {CLX-155: A Novel, Oral 5-FU Prodrug Displaying Antitumor Activity in Human Colon Cancer Xenograft Model in Nude Mice},
  journal = {Medical Research Archives},
  year = {2024},
  volume = {12},
  number = {6},
  doi = {10.18103/mra.v12i6.5219}
}
Kostenlos starten →